Advertisement

Clinical Pharmacokinetics

, Volume 58, Issue 2, pp 271–282 | Cite as

Population Pharmacokinetics of Gemtuzumab Ozogamicin in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia

  • Joanna C. MastersEmail author
  • Elly Barry
  • Beverly Knight
Original Research Article
  • 160 Downloads

Abstract

Background and Objective

To date, the population pharmacokinetics (popPK) of gemtuzumab ozogamicin (GO), a CD33-directed antibody–drug conjugate consisting of hP67.6 antibody linked to N-acetyl gamma calicheamicin used in the treatment of acute myeloid leukemia (AML), has not been characterized in pediatric patients. This report describes the popPK of GO following intravenous administration in 29 pediatric patients aged ≤ 17 years with relapsed or refractory AML who were enrolled in the 0903A1-102-US phase I/II study.

Methods

The pharmacokinetics (PK) of GO, as represented by total hP67.6 antibody, were described by a two-compartment model with two clearance components: a linear clearance (CL1) and time-dependent clearance that includes a decay coefficient. The PK of unconjugated calicheamicin (UC; payload) were described by a two-compartment model with CL1 and an input rate of formation based on antibody rate of elimination. Allometric scaling was included in both models, with baseline body weight as a fixed effect on CL1 and central volume.

Results and Conclusions

PK parameters for hP67.6 and UC were not significantly affected by any of the available demographic factors and safety laboratory values tested as covariates (except baseline body weight). Simulations to compare GO dosing regimens (6, 7.5, and 9 mg/m2 on days 1 and 15 versus, 3 mg/m2 fractionated dosing on days 1, 4, and 7) were performed, showing that total antibody and UC trough concentrations were maintained at higher concentrations during treatment following the more frequent dosing than following the original regimen.

Study Identifier

0903A1-102-US.

Notes

Acknowledgements

The authors thank Ana Ruiz-Garcia (Pfizer Inc.) for guidance in modeling techniques and review of the manuscript. Editorial support was provided by Susan Reinwald, PhD, and Kevin O’Regan, PhD, of Complete Healthcare Communications, LLC, and David Wateridge, PhD, of Engage Scientific Solutions, and was funded by Pfizer.

Compliance with Ethical Standards

Funding

This study was funded by Pfizer Inc. Open-access publication of this manuscript was sponsored by Pfizer.

Conflict of interest

JCM, EB, and BK are full-time employees of Pfizer and have stock ownership.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from all patients (or their parent/guardian) included in the 0903A1-102-US study. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

Supplementary material

40262_2018_694_MOESM1_ESM.docx (588 kb)
Supplementary material 1 (DOCX 588 kb)

References

  1. 1.
    MYLOTARG™ (gemtuzumab ozogamicin). New York: Pfizer Inc.; 2017.Google Scholar
  2. 2.
    Cowan AJ, Laszlo GS, Estey EH, et al. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed). 2013;18:1311–34.Google Scholar
  3. 3.
    Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011;17(20):6417–27.Google Scholar
  4. 4.
    Zwaan CM, Reinhardt D, Zimmerman M, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 2010;148(5):768–76.Google Scholar
  5. 5.
    Zwaan C, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood. 2003;101:3868–71.Google Scholar
  6. 6.
    Brethon B, Yakouben K, Oudot C, et al. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol. 2008;143(4):541–7.Google Scholar
  7. 7.
    Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–6.Google Scholar
  8. 8.
    Magwood-Golston JS, Kessler S, Bennett CL. Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res. 2016;44:61–4.Google Scholar
  9. 9.
    Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60.Google Scholar
  10. 10.
    van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97(10):3197–204.Google Scholar
  11. 11.
    van der Velden VH, Boeckx N, Jedema I, et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia. 2004;18(5):983–8.Google Scholar
  12. 12.
    Amadori S, Suciu S, Selleslag D, et al. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol. 2010;149(3):376–82.Google Scholar
  13. 13.
    Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–16.Google Scholar
  14. 14.
    EU Clinical Trials Register. International randomised phase III clinical trial in children with acute myeloid leukaemia—incorporating an embedded dose finding study for gemtuzumab ozogamicin in combination with induction chemotherapy [EudraCT 2014-005066-30]. 2016. https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005066-30/GB. Accessed 16 Apr 2018.
  15. 15.
    ClinicalTrials.gov. International randomised phase III clinical trial in children with acute myeloid leukaemia (Myechild01) [ClinicalTrials.gov identifier NCT02724163]. 2017. https://clinicaltrials.gov/ct2/show/NCT02724163. Accessed 16 Apr 2018.
  16. 16.
    Hibma J, Knight B. Population pharmacokinetic modeling of gemtuzumab ozogamicin in adult patients with acute myeloid leukemia. Clin Pharmacokinet. 2018.  https://doi.org/10.1007/s40262-018-0699-5.Google Scholar
  17. 17.
    Dowell JA, Korth-Bradley J, Liu H, et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol. 2001;41(11):1206–14.Google Scholar
  18. 18.
    Perl speaks NONMEM (PsN4). 2017. https://uupharmacometrics.github.io/PsN/docs.html. Accessed 16 Apr 2018.
  19. 19.
    Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329–32.Google Scholar
  20. 20.
    Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165(12):819–29.Google Scholar
  21. 21.
    Knebel W, Corcoran M, Ermer J, et al. Population pharmacokinetic modeling of guanfacine in pediatric patients. Clin Pharmacokinet. 2015;54(8):875–83.Google Scholar
  22. 22.
    Ahn JE, Karlsson MO, Dunne A, et al. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35(4):401–21.Google Scholar
  23. 23.
    De Cock RF, Piana C, Krekels EH, et al. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67(suppl 1):5–16.Google Scholar
  24. 24.
    Gibiansky E, Gibiansky L, Carlile DJ, et al. Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma and exposure-response in CLL. CPT Pharmacometrics Syst Pharmacol. 2014;3:e144.Google Scholar
  25. 25.
    Levi M, Li J, Frey N, et al. Characterization of the time-varying clearance of rituximab in non-Hodgkin’s lymphoma patients using a population pharmacokinetic analysis. 2008. http://www.acop7.org/assets/Legacy_ACOPs/2008ACOP/PostersandAbstracts/9_levi.ppt. Accessed 16 Apr 2018.
  26. 26.
    Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children’s oncology group phase I consortium. J Clin Oncol. 2011;29(7):839–44.Google Scholar
  27. 27.
    Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children’s Oncology Group. Cancer. 2012;118(3):761–9.Google Scholar
  28. 28.
    Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 2007;21(1):66–71.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Clinical Pharmacology, Oncology, Global Product DevelopmentPfizer IncSan DiegoUSA
  2. 2.Pfizer Global Product Development OncologyCambridgeUSA

Personalised recommendations